News

Novira is focused on the discovery and development of therapies to treat chronic hepatitis B (CHB) infection. The company’s novel antiviral drug candidates have the potential to address

Sanofi will pay Hanmi €400m up front and possibly a further €3.5bn in development, registration and sales milestones, in addition to double digit royalties on net sales. In

Under the JAVELIN Lung 100 study, the companies aim to assess the safety and efficacy of avelumab compared with platinum-based doublet chemotherapy, in patients with late-stage NSCLC who

Nucala is approved as an add-on maintenance treatment for patients aged 12 and older. It is administered once every four weeks by injection. The drug is a monoclonal

The project intends to sequence 100,000 whole genomes from about 70,000 are participants with various types of cancer or rare diseases. Participants are NHS patients with a rare

According to a recent study done by UCLA, most diet efforts result in very short-term weight loss or even weight gain. Other research has shown that 50-60% of

Both technologies originate from the pioneering work of Don J. Diamond, Ph.D., chair of the Department of Experimental Therapeutics at City of Hope, an independent biomedical research institution

As per the terms of the licensing deal, Allergan will fund phase 3 development of tavilermide. Mimetogen will receive an upfront payment of $50m from Allergan. The deal

Under terms of the agreement, GenomOncology’s GO Clinical Workbench™ will now support interpretation of multiple ArcherDX assays, including ALK, RET, ROS1, Solid Tumor, and Comprehensive Thyroid and Lung